Annexon (NASDAQ:ANNX) Director Acquires $46,240.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) Director William Carson purchased 8,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $5.78 per share, with a total value of $46,240.00. Following the transaction, the director owned 78,405 shares in the company, valued at $453,180.90. The trade was a 11.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Annexon Stock Performance

Shares of ANNX traded up $0.01 during trading hours on Wednesday, hitting $5.45. The company had a trading volume of 2,253,481 shares, compared to its average volume of 2,527,612. The firm has a fifty day moving average price of $5.70 and a 200-day moving average price of $5.14. The stock has a market capitalization of $892.93 million, a price-to-earnings ratio of -4.47 and a beta of 1.22. Annexon, Inc. has a 52-week low of $1.67 and a 52-week high of $7.18.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.07. Research analysts anticipate that Annexon, Inc. will post -1.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on ANNX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research report on Monday, April 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Chardan Capital reissued a “buy” rating and issued a $16.00 target price on shares of Annexon in a research report on Friday, March 20th. Wall Street Zen raised Annexon from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, The Goldman Sachs Group began coverage on Annexon in a research report on Tuesday. They issued a “neutral” rating and a $7.00 target price for the company. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Annexon presently has an average rating of “Hold” and a consensus price target of $16.00.

Hedge Funds Weigh In On Annexon

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after buying an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in shares of Annexon during the 4th quarter valued at about $50,000. CIBC Bancorp USA Inc. bought a new stake in shares of Annexon during the 3rd quarter valued at about $31,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Annexon during the 4th quarter valued at about $52,000. Finally, Mount Vernon Associates Inc. MD bought a new stake in shares of Annexon during the 4th quarter valued at about $53,000.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: HC Wainwright raised its earnings-per-share estimates across multiple periods, including FY2026, FY2027, FY2028, and FY2029, signaling improved expectations for Annexon’s future profitability. Annexon analyst estimate revisions
• Positive Sentiment: The FY2029 estimate was upgraded from a loss to a profit, which may reassure investors that Annexon could be moving toward breakeven over the long term. Annexon long-term earnings outlook
• Neutral Sentiment: Goldman Sachs upgraded Annexon to “hold,” which is a modestly constructive but not strongly bullish signal for the shares. Goldman Sachs upgrade to hold
• Negative Sentiment: Despite the improved estimates, Annexon is still expected to post losses in the near term, so the company remains a speculative turnaround story rather than a profitable business today. Annexon earnings outlook

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.